List Strengths :

1. Good financial ability

On the stock market on January 21, 2022, DHG's shares were VND 102,100/share.

The audited financial statements for 2021 of DHG Pharma recorded a full year's net revenue of
VND 4,003 billion

Having good relationships with big banks such as HSBC, Vietcombank, Incombank, etc.

2. Ability to be proactive about raw materials

20% of raw materials are self-sufficient instead of 10% in previous years, making it easier to be
proactive about the company's raw materials

3. Product quality meets the needs well

The year 2021 will be full of challenges for the pharmaceutical industry when the shortage of
raw materials due to the prolonged epidemic, production interruption and distribution difficulties
due to the quarantine order... However, enterprises still ensure the supply and production of
products. manufactures and distributes high-quality drugs for consumers. Outstanding products
of high standard include Hapacol pain reliever and fever reducer, Clabact and Zaromax
antibiotics, Neni nerve, Raxiom stomach, Vastec cardiovascular, Telfor allergy, Fubenzon
dewormer... During this 4th epidemic 10 million Hapacol 650 tablets were given to accompany
people to vaccinate.

4. Reasonable price policies has a high competitive

The income of Vietnamese people is consistent with domestic drugs with the same quality as
imported ones, but the price is only 30-50%.

5. Advanced production machinery

The system of factories, modern sewing lines, and advanced technology meets GMP-WHO,
GLP, GSP standards certified by the Vietnam Drug Administration.

List Weaknesses :

1. Marketing activities are not focused

Although DHG's key products have been invested in branding, the awareness level is still low,
compared to other competitors because these companies invest heavily in advertising activities,
especially advertising on the Internet. TV.

2. Product quality management is not good

The selling price of products is strictly controlled by the state. Some policies in industry
management are not synchronized and incomplete, so enterprises often face confusion when
implementing. When analyzing the factors affecting the product, it is still unclear, leading to
weaknesses that create a lot of competition for the company's products with other competitors.

3. Maximum unused production capacity

Health care awareness and drug spending per capita is increasing with the high growth rate of
the pharmaceutical industry, but the market share of manufactured drugs is not enough to meet
the needs of the domestic population.

4. Research and development of new products is still weak

Most companies only focus on preparation technology, overlapping with other pharmaceutical
companies in product lines, but have not developed a source of medicinal herbs, paying little
attention to specialized drugs, specific dosage forms. separate.

5. Distribution channels are limited

The distribution system is still limited with 36 branches distributing goods across the country
from urban to rural areas (distribution to 3 floors: city, district, commune) with more than 27,000
customers. But there is still no real drug distribution subsidiary with professionalism, modern
technology, and perfect preferential service.